The February, 2012 issue of Life Science Leader has a wide-ranging interview with G. Steven Burrill. It's an interesting, insightful read, and we can recommend the interview. Mr. Burrill makes…
UPDATE (21 February) - Here is a decent video interview of Rachel Sherman, head of the Office of Medical Policy for the FDA, on the Biosimilar guidelines: BioCentury This Week Today…
Last week, the NY Times published an interesting article on the cause of Alzheimer's Disease. The article describes experiments in a new mouse model which may confirm, once and for…
Lacerta Bio has returned to cold, windy New York following a solid week in sunny, warm San Francisco. We blogged about last year's JP Morgan Healthcare conference here . For…
Last month, Lacerta Bio celebrated its first full year in existence. In fact, our coming out event was JP Morgan 2011. What have we learned in a year? Probably too…
Happy New Year, everyone! Next week, 2012 kicks off with the madness otherwise knows as JP Morgan, or #JPM12 if you prefer. We blogged about last year's conference here. Last…
We are busy preparing for the Annual Industry kickoff conference at the Westin in San Francisco. Currently, we are scheduling 30-minute meetings on behalf of our clients. Plus, we're planning…
As 2011 draws to a close, here are a few thoughts on 2011 and 2012: Uncertainty - If there is one word that captures the mood of the year, it…
Lacerta Bio was privileged to give a short talk at the first (and hopefully annual) Drug Delivery Summit in London late last month. While lightly attended, the two-day conference brought…
Pharmaceutical outsourcing to CROs is certainly nothing new. However, this week we learned that pharmaceutical giant Lilly and AMRI signed an interesting insourcing / outsourcing agreement. In this deal, AMRI…